GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 2cureX AB (OSTO:2CUREX) » Definitions » ROE %

2cureX AB (OSTO:2CUREX) ROE % : -180.27% (As of Sep. 2023)


View and export this data going back to 2017. Start your Free Trial

What is 2cureX AB ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. 2cureX AB's annualized net income for the quarter that ended in Sep. 2023 was kr-40.66 Mil. 2cureX AB's average Total Stockholders Equity over the quarter that ended in Sep. 2023 was kr22.55 Mil. Therefore, 2cureX AB's annualized ROE % for the quarter that ended in Sep. 2023 was -180.27%.

The historical rank and industry rank for 2cureX AB's ROE % or its related term are showing as below:

OSTO:2CUREX' s ROE % Range Over the Past 10 Years
Min: -94.59   Med: -26.04   Max: -5.85
Current: -94.59

During the past 8 years, 2cureX AB's highest ROE % was -5.85%. The lowest was -94.59%. And the median was -26.04%.

OSTO:2CUREX's ROE % is ranked worse than
72.69% of 1366 companies
in the Biotechnology industry
Industry Median: -43.41 vs OSTO:2CUREX: -94.59

2cureX AB ROE % Historical Data

The historical data trend for 2cureX AB's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

2cureX AB ROE % Chart

2cureX AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE %
Get a 7-Day Free Trial -42.91 -38.05 -16.84 -28.43 -50.73

2cureX AB Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -46.40 -60.76 -76.99 -103.48 -180.27

Competitive Comparison of 2cureX AB's ROE %

For the Biotechnology subindustry, 2cureX AB's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


2cureX AB's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 2cureX AB's ROE % distribution charts can be found below:

* The bar in red indicates where 2cureX AB's ROE % falls into.



2cureX AB ROE % Calculation

2cureX AB's annualized ROE % for the fiscal year that ended in Dec. 2022 is calculated as

ROE %=Net Income (A: Dec. 2022 )/( (Total Stockholders Equity (A: Dec. 2021 )+Total Stockholders Equity (A: Dec. 2022 ))/ count )
=-29.77/( (74.344+43.034)/ 2 )
=-29.77/58.689
=-50.73 %

2cureX AB's annualized ROE % for the quarter that ended in Sep. 2023 is calculated as

ROE %=Net Income (Q: Sep. 2023 )/( (Total Stockholders Equity (Q: Jun. 2023 )+Total Stockholders Equity (Q: Sep. 2023 ))/ count )
=-40.656/( (27.362+17.743)/ 2 )
=-40.656/22.5525
=-180.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2023) net income data. ROE % is displayed in the 30-year financial page.


2cureX AB  (OSTO:2CUREX) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-40.656/22.5525
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-40.656 / 0.348)*(0.348 / 25.624)*(25.624 / 22.5525)
=Net Margin %*Asset Turnover*Equity Multiplier
=-11682.76 %*0.0136*1.1362
=ROA %*Equity Multiplier
=-158.89 %*1.1362
=-180.27 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-40.656/22.5525
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-40.656 / -40.652) * (-40.652 / -36.992) * (-36.992 / 0.348) * (0.348 / 25.624) * (25.624 / 22.5525)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0001 * 1.0989 * -10629.89 % * 0.0136 * 1.1362
=-180.27 %

Note: The net income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


2cureX AB ROE % Related Terms

Thank you for viewing the detailed overview of 2cureX AB's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


2cureX AB (OSTO:2CUREX) Business Description

Traded in Other Exchanges
Address
Fruebjergvej 3, Copenhagen, DNK, DK-2100
2cureX AB is a biotech company. The company is engaged in improving treatment efficiency, mainly for cancer patients. It is involved in developing a product, namely IndiTreat, which is a technology for the treatment of colorectal, ovarian, and pancreatic cancers. The company's sub-products include IndiTreat Test, IndiTreat clinical programs, and IndiTreat Therapy Design.

2cureX AB (OSTO:2CUREX) Headlines

No Headlines